

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

BUSINESS UPDATE — TERMINATION OF EXCLUSIVE LICENSE AGREEMENT WITH ASTRAZENECA IN RESPECT OF BYETTA AND BYDUREON

Reference is made to the announcement of 3SBio Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 11 October 2016 in relation to the discloseable transaction regarding the Exclusive License Agreement with AstraZeneca (the “**Announcement**”) for the Commercialization of the Licensed Products under the Exclusive License Agreement and the announcement of the Company dated 5 February 2021 in relation to the cessation of license arrangement regarding the Commercialization of the Bydureon Licensed Product. Unless otherwise defined, the terms adopted in this announcement shall have the same meaning as those defined in the Announcement.

The Company wishes to update its Shareholders that due to further streamlining of the relevant Licensed Products, Hongkong Sansheng and AstraZeneca entered into a termination agreement on 28 February 2023 to agree that, with effect from 31 December 2023 (the “**Termination Date**”), the Exclusive License Agreement shall be terminated and the Commercialization of the Licensed Products thereunder shall cease, save that the distribution by the third party distributors of Byetta Licensed Products acquired by such third party distributors prior to the Termination Date shall cease on 31 August 2025.

The Board considers that the termination of the Exclusive License Agreement and the cessation of the arrangements in relation to the Commercialization of the Byetta Licensed Products have no material impact on the business operation and financial position of the Group as the financial contributions by the Byetta Licensed Products to the Group have been nominal.

The Group will continue to explore other collaboration and business opportunities with reputable pharmaceutical companies and distributors like AstraZeneca and other major industry players.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Hong Kong, 28 February 2023

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi, Mr. Ng, Joo Yeow Gerry and Dr. Zhang Dan as independent non-executive Directors.